Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc1412654 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Angiotensin Receptor-Neprilysin Inhibitor Prescribing Patterns in Patients Hospitalized for Heart Failure.
JAMA Cardiol
December 2024
Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, Los Angeles, California.
Importance: Angiotensin receptor-neprilysin inhibition (ARNI) improves mortality among patients with heart failure with reduced ejection fraction (HFrEF), ie, those with an EF of 40% or less.
Objective: To describe national longitudinal trends in ARNI prescribing patterns among hospitalized patients with HFrEF.
Design, Setting, And Participants: Using data from the Get With The Guidelines-Heart Failure (GWTG-HF) registry, hospitalized patients with HFrEF at 614 participating hospitals were identified.
Impact of Sacubitril/Valsartan in Improving Home Time for Patients With Heart Failure.
Cureus
November 2024
Cardiology, Fortis Hospital, Gurgaon, IND.
Article Synopsis
- Home time, or the duration patients with cardiovascular disease spend alive outside of healthcare institutions, is an essential aspect of recovery, particularly for heart failure (HF) patients, yet insufficiently studied in India where HF rates are increasing.
- Current literature falls short in identifying hospital-level trends and predictors of home time, which complicates the development of personalized care strategies to enhance health outcomes, functional status, and reduce hospitalization risks.
- While guideline-directed medical therapy, especially sacubitril/valsartan (an angiotensin receptor neprilysin inhibitor), is well-supported for improving life quality and reducing HF-related hospitalizations, its use remains low, indicating a critical need for better integration into clinical practice to improve patient recovery and home time post
The impact of angiotensin-receptor neprilysin inhibitors on cardiovascular events and solute transport function in peritoneal dialysis patients: a multicenter retrospective controlled study.
Ren Fail
December 2024
Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Background: Whether angiotensin receptor-neprilysin inhibitor (ARNI) can reduce the incidence of cardiovascular events and improve peritoneal function in peritoneal dialysis (PD) patients remains unclear. Thus, this study aims to clarify the role of ARNI in PD patients.
Methods: This was a multicenter retrospective study.
Phosphodiesterase 9 Inhibition Combined With Valsartan and With Sacubitril/Valsartan in Experimental Ovine Heart Failure.
J Am Heart Assoc
December 2024
Department of Medicine Christchurch Heart Institute, University of Otago-Christchurch Christchurch New Zealand.
Background: LCZ696 (sacubitril/valsartan) antagonizes the renin-angiotensin system while simultaneously augmenting the natriuretic peptides (NPs). Inhibition of phosphodiesterase 9 inhibition (PDE9i), which hydrolyses NP-generated cGMP may be a more specific means of enhancing NP bioactivity. The objective of the present study was to compare for the first time effects of LCZ696 and PDE9i+valsartan in experimental heart failure (HF) and investigate combination PDE9i+LCZ696.
View Article and Find Full Text PDFAngiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum: The PARAGON-HF Trial.
JACC Heart Fail
November 2024
Harvard Medical School, Boston, Massachusetts, USA; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Background: Lower estimated glomerular filtration rate (eGFR) may be one of the major reasons for hesitation or failure to initiate potentially beneficial therapies in patients with heart failure (HF).
Objectives: This study sought to assess if the effects of sacubitril/valsartan (vs valsartan) on cardiovascular outcomes differ according to baseline kidney function in patients with HF with preserved ejection fraction.
Methods: The PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction) trial was global clinical trial of 4,796 patients with chronic HF and left ventricular ejection fraction (LVEF) ≥45% randomly assigned to sacubitril/valsartan or valsartan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!